INTRODUCTION: Oculomotor behaviors linked to cognitive performance revealed neurocognitive features of AD that can enhance the accuracy of its assessment and diagnosis. METHODS: A sample of 107 participants (i.e., 65 MCI and 42 controls) were recruited and followed up for 40 months. At baseline, they underwent assessment with the ViewMind digital biomarker, which draws cognitive related patterns of eye movement while people perform the Visual Short-Term Memory Binding task. RESULTS: Baseline data predicted that 36 MCI patients would progress to the AD clinical syndrome (ADS, AD Progressing). The remaining 29 MCI patients were predicted to remain as MCI or progress to other forms of dementia. After 40-months of follow up, 94% of ADS Progressing patients had received a diagnosis of dementia where none of the non-ADS Progressing had. DISCUSSION: The analysis of eye movement behavior combined with cognitive markers for AD can effectively predict progression to ADS among patients with MCI.
|Number of pages||11|
|Journal||Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring|
|Publication status||Published - 22 Dec 2022|
- mild cognitive impairment (MCI)
- conversion to Alzheimer Disease Syndrome
- follow up study
- digital biomarker